Patients with conditions involving memory loss may soon be able to benefit from a new therapy.
BPN14770 -- an experimental compound drug developed by Tetra Discovery Partners with backing from the National Institutes for Health's (NIH) Neurotherapeutics Network -- recently moved into the Phase I clinical study phase. The study is funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the NIH’s National Institute on Aging.
“We are pleased that BPN14770 has moved into a clinical study, and we are eagerly awaiting the outcomes of the safety trial,” Dr. Amir Tamiz, program director at NINDS, said.
BPN14770 is a modulator of PDE4D, an enzyme involved in the formation of connections between brain cells. Researchers hope it will someday be used in the treatment of patients suffering from dementia and Alzheimer’s disease.
Should the clinical study prove BPN14770 to be safe and potentially effective, the next step toward approval would be testing its effects on long-term memory and cognition.
